Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Rurik, Joel G
Hancock, Aidan S
Leibowitz, Michael S
Morley, Michael P
Linares Saldana, Ricardo A
Bolar, Nikhita A
Smith, Cheryl L
June, Carl H
Margulies, Kenneth B
Albelda, Steven M
Epstein, Jonathan A
MetadataShow full item record
AbstractFibrosis is observed in nearly every form of myocardial disease1. Upon injury, cardiac fibroblasts in the heart begin to remodel the myocardium by depositing excess extracellular matrix, resulting in increased stiffness and reduced compliance of the tissue. Excessive cardiac fibrosis is an important factor in the progression of various forms of cardiac disease and heart failure2. However, clinical interventions and therapies that target fibrosis remain limited3. Here we demonstrate the efficacy of redirected T cell immunotherapy to specifically target pathological cardiac fibrosis in mice. We find that cardiac fibroblasts that express a xenogeneic antigen can be effectively targeted and ablated by adoptive transfer of antigen-specific CD8+ T cells. Through expression analysis of the gene signatures of cardiac fibroblasts obtained from healthy and diseased human hearts, we identify an endogenous target of cardiac fibroblasts-fibroblast activation protein. Adoptive transfer of T cells that express a chimeric antigen receptor against fibroblast activation protein results in a significant reduction in cardiac fibrosis and restoration of function after injury in mice. These results provide proof-of-principle for the development of immunotherapeutic drugs for the treatment of cardiac disease.
CitationNature. 2019;573(7774):430-433. doi:10.1038/s41586-019-1546-z.
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
PublisherNature publishing group(NPG)
PubMed Central IDPMC6752964
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities.
- Authors: Frangogiannis NG
- Issue date: 2019 Feb
- CD8<sup>+</sup>-T Cells With Specificity for a Model Antigen in Cardiomyocytes Can Become Activated After Transverse Aortic Constriction but Do Not Accelerate Progression to Heart Failure.
- Authors: Gröschel C, Sasse A, Monecke S, Röhrborn C, Elsner L, Didié M, Reupke V, Bunt G, Lichtman AH, Toischer K, Zimmermann WH, Hasenfuß G, Dressel R
- Issue date: 2018
- Innate Immunity Effector Cells as Inflammatory Drivers of Cardiac Fibrosis.
- Authors: Baci D, Bosi A, Parisi L, Buono G, Mortara L, Ambrosio G, Bruno A
- Issue date: 2020 Sep 28
- Featured Article: TGF-β1 dominates extracellular matrix rigidity for inducing differentiation of human cardiac fibroblasts to myofibroblasts.
- Authors: Cho N, Razipour SE, McCain ML
- Issue date: 2018 Apr
- Antifibrotic response of cardiac fibroblasts in hypertensive hearts through enhanced TIMP-1 expression by basic fibroblast growth factor.
- Authors: Kinoshita T, Ishikawa Y, Arita M, Akishima-Fukasawa Y, Fujita K, Inomata N, Suzuki T, Namiki A, Mikami T, Ikeda T, Yamazaki J, Ishii T, Akasaka Y
- Issue date: 2014 Mar-Apr